製品名:4-Chloro-6-(methoxymethyl)-2-phenylpyrimidine

IUPAC Name:4-chloro-6-(methoxymethyl)-2-phenylpyrimidine

CAS番号:325685-59-4
分子式:C12H11ClN2O
純度:95%
カタログ番号:CM275170
分子量:234.68

包装単位 有効在庫 価格(USD) 数量
CM275170-250mg in stock țȁ
CM275170-1g in stock Ǝƀư
CM275170-5g 1-2 Weeks ȬŴƎ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:325685-59-4
分子式:C12H11ClN2O
融点:-
SMILESコード:COCC1=CC(Cl)=NC(C2=CC=CC=C2)=N1
密度:
カタログ番号:CM275170
分子量:234.68
沸点:
MDL番号:
保管方法:

Category Infos

Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.
Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Selatogrel
Selatogrel is an investigational, potent, fast-acting, reversible, and highly selective P2Y12 inhibitor, being developed for the treatment of an acute myocardial infarction (AMI) in patients with a recent history of AMI. It is intended to be self-administered subcutaneously via a drug delivery system (autoinjector).
This novel, self-administered emergency agent has the potential to protect heart muscle in the very early phase of an AMI – in the crucial time between symptom onset and first medical attention – so as to treat the ongoing AMI and prevent early death.

Related Products